Health ❯ Healthcare ❯ Clinical Trials
Drug Efficacy Phase 3 Trials Alzheimer's Research Nature Medicine Publications Mid-Stage Trials Real-World Evidence Liraglutide Efficacy Blood Pressure Positioning Weight Management Vision Improvement Puberty Blockers Research Georgetown University Study Placebo-Controlled Trials Alcohol Consumption Bacterial Vaginosis Treatment Trials Lenacapavir Trials STAMP Trial AstraZeneca Alzheimer's Drug Pipeline Biomarker Testing Phase Two Studies Baxdrostat Randomized Trials Diagnostic Imaging Nutritional Science Statin Side Effects Blood Biomarkers Blood Biomarker Challenge Exercise Interventions RUBY Trial Dementia Prevention Trial Results Parkwood Hospital Drug Testing Cancer Research Mifepristone Late-Stage Clinical Trials Diabetes Management Proteotype Diagnostics Novo Nordisk Medication Efficacy FLOW Trial Cochrane Reviews Medical Innovations Multidisciplinary Research Trial Participants BackInAction Study PRIME Trial Prostate Cancer Screening Efficacy Testing Alzheimer Management by Albumin Replacement Cannabis Research Density MATTERS Trial INTEGUMENT-PED Study Alzheimer's Disease Detection NIH Studies Treatment Options Ivermectin Safety Trials FDA Approval TARGET-D Trial Future Implications Pathways Research Programme Tezepelumab Cognitive Decline DREAMS-1 Trial mRNA Therapy Elsa Study Animal Models ImPrEP LEN Brasil IQWiG Patient Recruitment Eli Lilly UFRJ Research HIV Prevention Trials Spinal Cord Injury PURPOSE 2 Trial Alzheimer's Blood Test Study
Findings point to a strong signal in HFpEF, a hard-to-treat subtype, spurring calls for confirmatory trials.
